Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SABR Oligo-ACC Trial: A Randomized Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma

NCT07845097 is registered in ClinicalTrials.gov with All India Institute of Medical Sciences as lead sponsor.

NCT NCT07845097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07845097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SABR Oligo-ACC Trial: A Randomized Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma
Lead sponsor
All India Institute of Medical Sciences
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 20, 2026
Completion date
December 20, 2032
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, oligometastatic